Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,879 | 2,950 | 264 | 46 | 146 |
| Other current assets | 3 | 0 | 0 | 6 | 6 |
| TOTAL | $2,037 | $3,156 | $556 | $306 | $445 |
| Non-Current Assets | |||||
| PPE Net | 5 | 2 | 1 | 3 | 5 |
| Other Non-Current Assets | 0 | 0 | 0 | 34 | 34 |
| TOTAL | $5 | $2 | $1 | $37 | $39 |
| Total Assets | $2,042 | $3,158 | $557 | $343 | $484 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 235 | N/A | N/A |
| Accounts payable and accrued liabilities | 77 | 199 | 101 | 990 | 680 |
| Accrued Expenses | 119 | 124 | 198 | 642 | 483 |
| Other current liabilities | 10,092 | N/A | 272 | 24 | 26 |
| TOTAL | $10,288 | $323 | $806 | $1,656 | $1,189 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 8,590 | 551 | 792 | 1,073 |
| TOTAL | $N/A | $8,590 | $551 | $792 | $1,073 |
| Total Liabilities | $10,288 | $8,912 | $1,357 | $2,448 | $2,262 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 531 | 530 | 400 | 124 | 122 |
| Common Shares | 133 | 132 | 34 | 31 | 30 |
| Retained earnings | -24,907 | -22,245 | -14,031 | -13,403 | -12,923 |
| Other shareholders' equity | 983 | 983 | 3,752 | 2,107 | 2,132 |
| TOTAL | $-8,245 | $-5,754 | $-800 | $-2,105 | $-1,778 |
| Total Liabilities And Equity | $2,042 | $3,158 | $557 | $343 | $484 |